ATARA BIOTHERAPEUTICS, INC. Increase (Decrease) in Deferred Revenue
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Increase (Decrease) in Deferred Revenue of $59.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was $91.00K.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$32.00K.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$295.00K.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was -$596.00K, a 106.88% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2025 was -$94.38M.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2024 was -$20.30M, a 166.80% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2023 was $30.39M.
- ATARA BIOTHERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2022 was -$11.47M, a 132.56% decline from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $91.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $59.00K 10-Q · filed 2026-08-12 | -$236.00K derived: sum of 3 quarters · filed 2026-08-12 | -$832.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$32.00K 10-Q · filed 2026-05-12 | -$327.00K derived: sum of 2 quarters · filed 2026-05-12 | -$923.00K derived: sum of 3 quarters · filed 2026-05-12 | -$15.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$891.00K derived: sum of 2 quarters · filed 2026-03-16 | -$15.27M derived: sum of 3 quarters · filed 2026-08-12 | -$94.38M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$596.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$14.97M derived: sum of 2 quarters · filed 2026-08-12 | -$94.08M 10-Q · filed 2025-11-12 | -$115.80M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$14.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$93.48M 10-Q · filed 2026-08-12 | -$115.21M derived: sum of 3 quarters · filed 2026-08-12 | -$106.54M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$79.11M 10-Q · filed 2026-05-12 | -$100.83M derived: sum of 2 quarters · filed 2026-05-12 | -$92.17M derived: sum of 3 quarters · filed 2026-05-12 | -$107.89M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$21.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$13.06M derived: sum of 2 quarters · filed 2026-03-16 | -$28.78M derived: sum of 3 quarters · filed 2026-03-16 | -$20.30M 10-K · filed 2026-03-16 |
| 2024-09-30 | $8.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$7.06M derived: sum of 2 quarters · filed 2025-11-12 | $1.42M 10-Q · filed 2025-11-12 | $31.27M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$15.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$7.25M 10-Q · filed 2025-08-11 | $22.61M derived: sum of 3 quarters · filed 2025-08-11 | $20.64M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $8.48M 10-Q · filed 2025-05-15 | $38.33M derived: sum of 2 quarters · filed 2025-05-15 | $36.36M derived: sum of 3 quarters · filed 2025-05-15 | $35.91M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $29.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $27.88M derived: sum of 2 quarters · filed 2025-03-07 | $27.43M derived: sum of 3 quarters · filed 2025-03-07 | $30.39M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.42M derived: sum of 2 quarters · filed 2024-11-12 | $540.00K 10-Q · filed 2024-11-12 | $40.54M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$451.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.51M 10-Q · filed 2024-08-12 | $42.51M derived: sum of 3 quarters · filed 2024-08-12 | $42.51M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $2.96M 10-Q · filed 2024-05-09 | $42.97M derived: sum of 2 quarters · filed 2024-05-09 | $42.97M derived: sum of 3 quarters · filed 2024-05-09 | -$7.98M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $40.00M derived: sum of 2 quarters · filed 2024-03-28 | -$10.94M derived: sum of 3 quarters · filed 2024-03-28 | -$11.47M 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$50.94M derived: sum of 2 quarters · filed 2023-11-01 | -$51.47M 10-Q · filed 2023-11-01 | -$13.07M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$50.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$51.47M 10-Q · filed 2023-08-08 | -$13.07M derived: sum of 3 quarters · filed 2023-08-08 | -$18.44M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$525.00K 10-Q · filed 2023-05-08 | $37.88M derived: sum of 2 quarters · filed 2023-05-08 | $32.51M derived: sum of 3 quarters · filed 2023-05-08 | $28.64M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $38.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $33.03M derived: sum of 2 quarters · filed 2023-02-08 | $29.16M derived: sum of 3 quarters · filed 2023-02-08 | $35.22M 10-K · filed 2023-02-08 |
| 2021-09-30 | -$5.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$9.24M derived: sum of 2 quarters · filed 2022-11-08 | -$3.18M 10-Q · filed 2022-11-08 | $58.07M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-06-30 | -$3.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.19M 10-Q · filed 2022-08-08 | $63.44M derived: sum of 3 quarters · filed 2023-02-08 | $63.44M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-03-31 | $6.06M 10-Q · filed 2022-05-05 | $67.31M derived: sum of 2 quarters · filed 2023-02-08 | $67.31M derived: sum of 3 quarters · filed 2023-02-08 | $67.31M derived: sum of 4 quarters · filed 2023-02-08 |
| 2020-12-31 | $61.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $61.25M derived: sum of 2 quarters · filed 2023-02-08 | $61.25M derived: sum of 3 quarters · filed 2023-02-08 | $61.25M 10-K · filed 2023-02-08 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |